Answers are grounded in this paper and cite their sources.
Background: Hypothyroidism is a common endocrine disorder characterized by reduced metabolic activity due to deficient thyroid hormone production. Despite the availability of hormone replacement therapy, many patients continue to experience symptoms and adverse effects. Ayurveda conceptualizes hypothyroidism as Garavisha Janya Dhatwagnimandya, where chronic exposure to incompatible diet, food additives, preservatives, and environmental toxins impairs Agni (digestive and metabolic fire), leading to Ama formation, Srotorodha (channel obstruction), and diminished tissue metabolism. Moorvadi Agad, described in Ashtanga Sangraha for Garavisha, possesses Vishaghna, Deepana, Pachana, and Srotoshodhana properties. This study evaluated its efficacy in managing Garavisha Janya Dhatwagnimandya (Hypothyroidism). Methods: A prospective, interventional, single-arm clinical trial was conducted on 30 patients aged 1860 years with primary hypothyroidism (TSH >5.4 µIU/mL and <15 µIU/mL) and a history of Garavisha exposure. Participants received Moorvadi Agad Churna 3 g orally thrice daily before meals with lukewarm water for 60 days. Assessment included subjective symptom scoring (general weakness, tiredness, hair loss, constipation, dyspnoea, hoarseness, menstrual abnormality, dry skin, cold intolerance, swelling, bradycardia) and objective parameters (TSH, T3, T4, BMI, body weight) at baseline and post-treatment. Data were analyzed using the Wilcoxon signed-rank test and paired t-test. Results: The mean TSH level decreased significantly from 12.37±8.66 mIU/L to 5.64±5.49 mIU/L (54.42% reduction, p<0.001). Overall subjective symptom score improved by 82.8% (p<0.001), with excellent relief in hoarseness (90.4%), constipation (90.1%), menstrual abnormalities (89.2%), hair loss (84.7%), dry skin (83.4%), swelling (83.3%), cold intolerance (82.8%), dyspnoea (80.8%), tiredness (80.0%), and general weakness (78.7%). BMI decreased from 24.29±2.49 to 23.35±2.24 (3.87% reduction, p<0.0001), and body weight reduced from 68.90±10.64 kg to 65.93±10.06 kg (4.31% reduction, p<0.0001). No adverse drug reactions were reported. Conclusion: Moorvadi Agad demonstrated significant efficacy and safety in managing Garavisha Janya Dhatwagnimandya (Hypothyroidism), offering a holistic approach addressing the underlying metabolic dysfunction and toxic burden.
No takes yet. Share an insight, caveat, or question.
Sen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: